Zoetis Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Zoetis Inc. (ZTS) reported Cash and Cash Equivalents, Period Increase (Decrease) of $332.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-13.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-02-13
- Zoetis Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-12-31 was $119.00M, a 62.34% decline year-over-year.
- Zoetis Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $60.00M.
- Zoetis Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $27.00M.
- Zoetis Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $126.00M, a 40.00% increase year-over-year.
- Zoetis Inc. cash and cash equivalents, period increase (decrease) for fiscal 2019 was $332.00M, a 773.68% increase from fiscal 2018.
- Zoetis Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $38.00M, a 95.46% decline from fiscal 2017.
- Zoetis Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $837.00M.
- Zoetis Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$427.00M, a 256.99% decline from fiscal 2015.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-12-31 | $119.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $179.00M derived: sum of 2 quarters · filed 2020-02-13 | $206.00M derived: sum of 3 quarters · filed 2020-02-13 | $332.00M 10-K · filed 2020-02-13 |
| 2019-09-30 | $60.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $87.00M derived: sum of 2 quarters · filed 2019-11-07 | $213.00M 10-Q · filed 2019-11-07 | $529.00M derived: sum of 4 quarters · filed 2020-02-13 |
| 2019-06-30 | $27.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $153.00M 10-Q · filed 2019-08-06 | $469.00M derived: sum of 3 quarters · filed 2020-02-13 | $197.00M derived: sum of 4 quarters · filed 2020-02-13 |
| 2019-03-31 | $126.00M 10-Q · filed 2019-05-02 | $442.00M derived: sum of 2 quarters · filed 2020-02-13 | $170.00M derived: sum of 3 quarters · filed 2020-02-13 | $74.00M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-12-31 | $316.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $44.00M derived: sum of 2 quarters · filed 2020-02-13 | -$52.00M derived: sum of 3 quarters · filed 2020-02-13 | $38.00M 10-K · filed 2020-02-13 |
| 2018-09-30 | -$272.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$368.00M derived: sum of 2 quarters · filed 2019-11-07 | -$278.00M 10-Q · filed 2019-11-07 | -$695.00M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | -$96.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$6.00M 10-Q · filed 2019-08-06 | -$423.00M derived: sum of 3 quarters · filed 2020-02-13 | $853.00M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $90.00M 10-Q · filed 2019-05-02 | -$327.00M derived: sum of 2 quarters · filed 2020-02-13 | $949.00M derived: sum of 3 quarters · filed 2020-02-13 | $1.02B derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | -$417.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $859.00M derived: sum of 2 quarters · filed 2020-02-13 | $935.00M derived: sum of 3 quarters · filed 2020-02-13 | $837.00M 10-K · filed 2020-02-13 |
| 2017-10-01 | $1.28B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $1.35B derived: sum of 2 quarters · filed 2018-11-01 | $1.25B 10-Q · filed 2018-11-01 | $1.33B derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-07-02 | $76.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$22.00M 10-Q · filed 2018-08-02 | $54.00M derived: sum of 3 quarters · filed 2019-02-14 | $47.00M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-04-02 | -$98.00M 10-Q · filed 2018-05-02 | -$22.00M derived: sum of 2 quarters · filed 2019-02-14 | -$29.00M derived: sum of 3 quarters · filed 2019-02-14 | -$46.00M derived: sum of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | $76.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $69.00M derived: sum of 2 quarters · filed 2019-02-14 | $52.00M derived: sum of 3 quarters · filed 2019-02-14 | -$427.00M 10-K · filed 2019-02-14 |
| 2016-10-02 | -$7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$24.00M derived: sum of 2 quarters · filed 2017-11-02 | -$503.00M 10-Q · filed 2017-11-02 | $59.00M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-07-03 | -$17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$496.00M 10-Q · filed 2017-08-08 | $66.00M derived: sum of 3 quarters · filed 2018-02-15 | $114.00M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-04-03 | -$479.00M 10-Q · filed 2017-05-04 | $83.00M derived: sum of 2 quarters · filed 2018-02-15 | $131.00M derived: sum of 3 quarters · filed 2018-02-15 | $116.00M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $562.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $610.00M derived: sum of 2 quarters · filed 2018-02-15 | $595.00M derived: sum of 3 quarters · filed 2018-02-15 | $272.00M 10-K · filed 2018-02-15 |
| 2015-09-27 | $48.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $33.00M derived: sum of 2 quarters · filed 2016-11-03 | -$290.00M 10-Q · filed 2016-11-03 | -$6.00M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-06-28 | -$15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$338.00M 10-Q · filed 2016-08-05 | -$54.00M derived: sum of 3 quarters · filed 2017-02-16 | -$34.00M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-03-29 | -$323.00M 10-Q · filed 2016-05-06 | -$39.00M derived: sum of 2 quarters · filed 2017-02-16 | -$19.00M derived: sum of 3 quarters · filed 2017-02-16 | $53.00M derived: sum of 4 quarters · filed 2017-02-16 |
| 2014-12-31 | $284.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $304.00M derived: sum of 2 quarters · filed 2017-02-16 | $376.00M derived: sum of 3 quarters · filed 2017-02-16 | $272.00M 10-K · filed 2017-02-16 |
| 2014-09-28 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $92.00M derived: sum of 2 quarters · filed 2015-11-05 | -$12.00M 10-Q · filed 2015-11-05 | $209.00M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-06-29 | $72.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$32.00M 10-Q · filed 2015-08-06 | $189.00M derived: sum of 3 quarters · filed 2016-02-24 | $209.00M derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-03-30 | -$104.00M 10-Q · filed 2015-05-07 | $117.00M derived: sum of 2 quarters · filed 2016-02-24 | $137.00M derived: sum of 3 quarters · filed 2016-02-24 | $38.00M derived: sum of 4 quarters · filed 2016-02-24 |
| 2013-12-31 | $221.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $241.00M derived: sum of 2 quarters · filed 2016-02-24 | $142.00M derived: sum of 3 quarters · filed 2016-02-24 | $293.00M 10-K · filed 2016-02-24 |
| 2013-09-29 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$79.00M derived: sum of 2 quarters · filed 2014-11-10 | $72.00M 10-Q · filed 2014-11-10 | $256.00M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | -$99.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $52.00M 10-Q · filed 2014-08-12 | $236.00M derived: sum of 3 quarters · filed 2015-02-27 | $263.00M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | $151.00M 10-Q · filed 2014-05-13 | $335.00M derived: sum of 2 quarters · filed 2015-02-27 | $362.00M derived: sum of 3 quarters · filed 2015-02-27 | $355.00M derived: sum of 4 quarters · filed 2015-02-27 |
| 2012-12-31 | $184.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $211.00M derived: sum of 2 quarters · filed 2015-02-27 | $204.00M derived: sum of 3 quarters · filed 2015-02-27 | $238.00M 10-K · filed 2015-02-27 |
| 2012-09-30 | $27.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $20.00M derived: sum of 2 quarters · filed 2013-11-13 | $54.00M 10-Q · filed 2013-11-13 | |
| 2012-07-01 | -$7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $27.00M 10-Q · filed 2013-08-14 | ||
| 2012-04-01 | $34.00M 10-Q · filed 2013-05-15 | |||
| 2011-12-31 | $16.00M 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |